ReviewHaematologica2019
Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
Review in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- Erythrocytosis after SGLT2 inhibitor initiation and anticoagulated outcomes in atrial fibrillation: a real-world analysis with counterfactual modeling.Cardiovascular diabetology · 2026Article
- Metabolic Overdrive in Elite Sport: A Systems Model of AMPK-mTOR Oscillation, NADInternational journal of molecular sciences · 2026Review
- Associations between per- and polyfluoroalkyl chemicals and abdominal aortic calcification in middle-aged and older adults.Journal of advanced research · 2025Article
- New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?Haematologica · 2025Review
- Redefining chronic mountain sickness: insights from high-altitude research and clinical experience.Medical review (2021) · 2025Review
- PROMISE: Prognostic Radiomic Outcome Measurement in Acute Subdural Hematoma Evacuation Post-Craniotomy.Brain sciences · 2025Article
- Evaluating the association of ischemic ECG changes and CBC parameters in normal population.ARYA atherosclerosis · 2025Article
- Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?Endocrine connections · 2024Review
- Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.Journal of clinical medicine · 2024Review
- Benefit of phlebotomy and low-dose aspirin in the prevention of vascular events in patients withHaematologica · 2024Article
- Are coagulation profiles in Andean highlanders with excessive erythrocytosis favouring hypercoagulability?Experimental physiology · 2024Article
- Utility of next-generation sequencing in identifying congenital erythrocytosis in patients with idiopathic erythrocytosis.Frontiers in medicine · 2024Article
- Associations of Long-Term Exposure to PMToxics · 2023Article
- Prevalence and morphological subtype distributions of anaemia in a Chinese rural population: the Henan Rural Cohort study.Public health nutrition · 2023Article
- Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.Cancer chemotherapy and pharmacology · 2023Article
- Polycythemia vera disease profile in an African population-experience from a tertiary facility in Ghana.SAGE open medicine · 2023Article
- Correlation between the Outcome of Vitrectomy for Proliferative Diabetic Retinopathy and Erythrocyte Hematocrit Level and Platelet Function.Journal of clinical medicine · 2022Article
- Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.Cardiovascular diabetology · 2022Article
- [Analysis of related factors in secondary erythrocytosis of obstructive sleep apnea hypopnea syndrome in Gansu province].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2022Article
- Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Here we critically evaluate the role of elevated hematocrit as the principal determinant of thrombotic risk in polycythemia and erythrocytosis, defined by an expansion of red cell mass. Since red cell volume determination is no longer readily available, in clinical practice, polycythemia and erythrocytosis are defined by elevated hemoglobin and hematocrit. Thrombosis is common in Chuvash erythrocytosis and polycythemia vera. Although the increased thrombotic risk is assumed to be due to the elevated hematocrit and an associated increase in blood viscosity, thrombosis does not accompany most types of erythrocytosis. We review studies indicating that the occurrence of thrombosis in Chuvash erythrocytosis is independent of hematocrit, that the thrombotic risk is paradoxically increased by phlebotomy in Chuvash erythrocytosis, and that, when compared to chemotherapy, phlebotomy is associated with increased thrombotic risk in polycythemia vera. Inherited and environmental causes that lead to polycythemia and erythrocytosis are accompanied by diverse cellular changes that could directly affect thrombotic risk, irrespective of the elevated hematocrit. The pressing issue in these disorders is to define factors other than elevated hematocrit that determine thrombotic risk. Defining these predisposing factors in polycythemia and erythrocytosis should then lead to rational therapies and facilitate development of targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.